In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
In the latest session, Viridian Therapeutics Inc (NASDAQ: VRDN) closed at $16.53 down -3.90% from its previous closing price of $17.2. In other words, the price has decreased by -$3.90 from its previous closing price. On the day, 0.83 million shares were traded. VRDN stock price reached its highest trading level at $17.22 during the session, while it also had its lowest trading level at $16.12.
Ratios:
For a deeper understanding of Viridian Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 19.49 and its Current Ratio is at 19.49. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.04.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Wells Fargo on December 19, 2024, Downgraded its rating to Equal Weight and sets its target price to $27 from $37 previously.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 27 ’24 when Beetham Thomas W. bought 5,000 shares for $23.41 per share. The transaction valued at 117,050 led to the insider holds 6,000 shares of the business.
Mahoney Stephen F. bought 21,400 shares of VRDN for $499,262 on Sep 27 ’24. The President and CEO now owns 21,400 shares after completing the transaction at $23.33 per share. On Sep 13 ’24, another insider, Fairmount Funds Management LLC, who serves as the Director of the company, bought 1,600,000 shares for $18.75 each. As a result, the insider paid 30,000,000 and bolstered with 3,445,813 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VRDN now has a Market Capitalization of 1403382272 and an Enterprise Value of 996195968. For the stock, the TTM Price-to-Sale (P/S) ratio is 4495.71 while its Price-to-Book (P/B) ratio in mrq is 2.62. Its current Enterprise Value per Revenue stands at 3266.216 whereas that against EBITDA is -2.684.
Stock Price History:
The Beta on a monthly basis for VRDN is 0.58, which has changed by 0.10053265 over the last 52 weeks, in comparison to a change of 0.18634176 over the same period for the S&P500. Over the past 52 weeks, VRDN has reached a high of $27.20, while it has fallen to a 52-week low of $9.90. The 50-Day Moving Average of the stock is 4.38%, while the 200-Day Moving Average is calculated to be -2.83%.
Shares Statistics:
For the past three months, VRDN has traded an average of 749.72K shares per day and 788600 over the past ten days. A total of 81.65M shares are outstanding, with a floating share count of 73.61M. Insiders hold about 9.78% of the company’s shares, while institutions hold 103.72% stake in the company. Shares short for VRDN as of 1752537600 were 11639358 with a Short Ratio of 15.52, compared to 1749772800 on 11335016. Therefore, it implies a Short% of Shares Outstanding of 11639358 and a Short% of Float of 14.899999.
Earnings Estimates
The stock of Viridian Therapeutics Inc (VRDN) is currently drawing attention from 5.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$1.1, with high estimates of -$1.02 and low estimates of -$1.29.
Analysts are recommending an EPS of between -$3.65 and -$4.75 for the fiscal current year, implying an average EPS of -$4.11. EPS for the following year is -$3.73, with 12.0 analysts recommending between -$3.06 and -$4.68.
Revenue Estimates
A total of 8 analysts have provided revenue estimates for VRDN’s current fiscal year. The highest revenue estimate was $300k, while the lowest revenue estimate was $100k, resulting in an average revenue estimate of $155.88k. In the same quarter a year ago, actual revenue was $302k
